
- 18. A product according to claim 16 wherein the side walls are in the form of a continuous double wall extending the whole height of the internal cavity from the base wall to the mouth opening.
- 19. A product according to claim 16 wherein substantially cylindrical inner and outer walls are substantially concentric and coaxial.
- 20. A product according to claim 16 wherein lower and upper container parts which fit together with a seal which does not allow leakage or contamination of the contents, such lower and upper container parts comprising respective lower and upper inner and outer wall parts of the container which fit together when the upper and lower container parts are fitted together.
- 21. A product according to claim 16 made of plastics material and having an inner wall thickness ca. 1 2 mm, and an outer wall thickness ca. 1 2.5 mm.
- 22. A product according to claim 1 wherein the medicament content is a fluid which incorporates a solvent vehicle.
- 23. A product according to claim 22 wherein the solvent vehicle is a pharmaceutically acceptable oily vehicle.
- 24. A product according to claim 23 wherein the oily vehicle is a monoglyceride, phospholipid, or a galactolipid.
- 25. A product according to claim 23 wherein the oily vehicle is selected from glycerol mono-oleate, glycerol monopalmitate and glycerol monostearate.
- 26. A product according to claim 22 containing a long-chain digylyceride.
- 27. A product according to claims 22 containing a fatty acid triglyceride.



- 29. A product according to claim 16 wherein the medicament content comprises calcium mupirocin, fractionated coconut oil, and glycerol mono-oleate.
- 30. A product according to claim 16 being a nasal spray container provided with means to deliver its medicament content to the nasal area of a user. --

## **REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP99/00559 into the U.S. national phase of prosecution..

Claims 1-15 filed in January 2001, during the international phase have been cancelled and replaced with new claims 16-30. New claims 16-30 are written to comply with proper U.S. format and their addition is supported in the claims and specification as originally filed.

In view of the foregoing, favorable consideration of claims 16-30 are requested, early examination on the merits, and allowance of this application with claims 16-30 are earnestly solicited.

A Version with Markings to Show Changes Made is enclosed.

Respectfully submitted,

Nora Stein-Fernandez Attorney for Applicants

Registration No. 36,689

GLAXOSMITHKLINE Corporate Intellectual Property UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5044

Facsimile (610) 270-5090

n:\nsf\patapps\p31814\preamend.doc